SANOFI-AVENTIS (EPA:SAN) Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
Transparency directive : regulatory news
24/02/2024 15:51